VEGFA and glioblastoma: The ACRIN 6677/RTOG 0625 central reader study demonstrated that although progressive contrast enhancement in recurrent glioblastoma after 2-4 cycles of anti-VEGF therapy prognosticated poor survival, there was no significant survival benefit for contrast enhancement responders (decreasing enhancement) compared to non-responders, non-progressors (stable disease) (16).